Product Description
Currently, the oldest lipid-modifying drug, nicotinic acid (niacin), is attracting renewed attention as it has the strongest HDL cholesterol-elevating effect among the drugs currently approved for the treatment of lipid disorders. Nicotinic acid has been used for decades to treat dyslipidaemic states. In particular its ability to raise the plasma HDL cholesterol concentration has led to an increased interest in its pharmacological potential. The clinical use of nicotinic acid is somewhat limited due to several harmless but unpleasant side effects, most notably a cutaneous flushing phenomenon. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268066/)
Mechanisms of Action: 30S Ribosomal Subunit
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Italy | Korea | Lebanon | Malaysia | Malta | Mexico | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Cystic Fibrosis|Dyslipidemia|Hypercholesterolemia|Hypertriglyceridemia
Phase 1: Depressive Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12623000423617 |
ACTRN12623000423617 | P1 |
Not yet recruiting |
Depressive Disorder |
2024-11-30 |
2024-08-29 |
Treatments |
|
NCT06449677 |
BPCFRD | P3 |
Recruiting |
Cystic Fibrosis |
2025-11-01 |
15% |
2024-10-04 |
|
CTR20131900 |
CTR20131900 | P3 |
Recruiting |
Hypercholesterolemia|Dyslipidemia|Hypertriglyceridemia |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/08/2025 |
News Article |
Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026 |
|
11/21/2025 |
News Article |
MOEA Takes Home 7 Awards at R&D100 |
|
11/21/2025 |
News Article |
Pantene Introduces the All-New Abundant & Strong Collection to Reduce Hair Shedding and Grow Healthier, More Abundant Hair |
|
11/20/2025 |
News Article |
AI Market Poised to Hit $3.5 Trillion by 2033, Powered by 31.5% Annual Growth - Grand View Research |